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Abstract
Resected epileptic tissues exhibit elements of chronic neuroinflammation that include elevated
TNFα and increased TNFα receptor activation, but the seizure related consequences of chronic
TNFα expression remain unknown. Twenty four hours after acute limbic seizures the rat
hippocampus exhibited a rapid upregulation of TNFR1, but a simultaneous downregulation of
TNFR2. These limbic seizures also evoked significant increases in measures of
neuroinflammation and caused significant neuronal cell death in both the hilus and CA3 of the
hippocampus. In order to mimic a state of chronic TNFα exposure, adeno-associated viral vectors
were packaged with a TNF receptor 1 (TNFR1) specific agonist, human TNFα, or a TNF receptor
1/2 agonist, rat TNFα. Subsequently, chronic hippocampal overexpression of either TNFR ligand
caused microglial activation and blood-brain barrier compromise, a pattern similar to limbic
seizure-induced neuroinflammation. However, no evidence was found for neuronal cell death or
spontaneous seizure activity. Thus, chronic, in vivo TNFα expression and the subsequent
neuroinflammation alone did not cause cell death or elicit seizure activity. In contrast, chronic
hippocampal activation of TNFR1 alone significantly increased limbic seizure sensitivity in both
amygdala kainic acid and electrical amygdala kindling models, while chronic activation of both
TNFR1 and TNFR2 significantly attenuated the amygdala kindling rate. With regard to
endogenous TNFα, chronic hippocampal expression of a TNFα decoy receptor significantly
reduced seizure-induced cell death in the hippocampus, but did not alter seizure susceptibility.
These findings suggest that blockade of endogenous TNFα could attenuate seizure related
neuropathology, while selective activation of TNFR2 could exert beneficial therapeutic effects on
in vivo seizure sensitivity.
Introduction
Over the last decade, both clinical and basic research has directly linked neuroinflammatory
events with epilepsy (Vezzani et al. , 2012). Clinically, tissues resected from refractory
temporal lobe epileptics exhibit a number of neuroinflammatory changes, such as increased
IL-1β levels (Ravizza et al. , 2008), upregulated TNF-α receptor 1 (TNFR1) signaling
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pathways (Yamamoto et al. , 2006), increased CCL2 protein concentrations (Choi et al. ,
2009, Wu et al. , 2008), increased CSF levels of IL-6 (Lehtimaki et al. , 2004) and activated
astrocytes (Bordey and Sontheimer, 1998). Additional neuropathological consequences
include the presence of a compromised blood-brain barrier (BBB) and activated microglia
(Hufnagel et al. , 2003). Although these chronic neuropathologies inevitably contribute to
temporal lobe seizures, studies also have established direct in vivo seizure interactions for a
wide range of neuroimmune modulators from TNF-α and IL1-β to toll-like receptor-4 and
high mobility group box-1 (Dedeurwaerdere et al. , 2012).
A substantial literature suggests a direct role for TNF-α in seizure sensitivity, primarily
from basic research studies that utilized acute manipulation of TNF-α function or transgenic
mouse models. Balosso et al. (2005) found that acute, selective activation of TNFR1 by
human TNF-α exerted no influence on hippocampal seizure sensitivity, but activation of
both TNFR1 and TNFR2 by mouse TNF-α strongly inhibited seizure activity. Similarly,
mice deficient in TNFR2 or both TNFR2 and TNFR1 exhibited increased seizure sensitivity,
while astrocyte overexpression of TNF-α attenuated seizure sensitivity (Balosso et al. ,
2005). From these findings the authors concluded that activation of TNFR2 attenuates
seizure activity, while activation of TNFR1 did not influence seizure sensitivity. In contrast,
Probert et al (1995) reported that neuronal overexpression of TNF-α caused seizures and
premature death. Clearly, these studies provided substantial insight into TNF-α interactions
with seizures, but acute TNF-α manipulations do not faithfully recapitulate the clinical
finding of chronic TNFα exposure. Furthermore, with transgenic animal models the results
may be influenced by the likely developmental adaptation.
Adeno-associated virus (AAV) vectors provide the opportunity to mimic the chronic state of
elevated TNF-α in vivo and determine the influence of this chronic activation on in vivo
seizures. AAV vectors can non-toxically transduce cells in the CNS, and in most cases the
transduction is predominantly neuronal (McCown, 2010). Since AAV vectors alone do not
evoke significant neuroinflammation, gene expression would take place in the absence of
any vector influence on neuroimmune function (Gorbatyuk et al. , 2008, Wang et al. , 2010).
Thus, chronic vector-mediated TNF-α expression in the hippocampus should more closely
mimic conditions found in tissue resected from intractable temporal lobe epileptics. The
following studies characterized the influence of chronic TNF-α exposure, as well as the
interactions between seizures and TNFR1 or TNFR2. The results demonstrate clear,
opposing receptor-dependent actions of chronic TNF-α, and provide future directions for
treating the pathology associated with temporal lobe epilepsy.
Materials and Methods
Animals
The animals were male Sprague-Dawley rats (Charles River, Morrisville, NC, USA)
weighing between 275-300 grams. The rats were maintained in a 12-h light-dark cycle and
had free access to water and food. All care and procedures were in accordance with the
National Institutes of Health Guide for the Care and Use of Laboratory Animals and
received prior approval by the University of North Carolina Institutional Animal Care and
Usage Committee.
Amygdala kainic acid delivery and time course tissue collection
For intracranial kainic acid infusions, rats were anesthetized with isofluorane and placed into
a stereotaxic frame. Using a 32-gauge stainless steel injector and a Fisher Scientific infusion
pump, rats received 0.5 μl of 1 μg/μL kainic acid over 2.5 minutes (Cayman Chemical Co.,
Ann Arbor, MI, USA, in 0.9% saline) to the right amygdala (bregma -2.7 mm, lateral - 4.5
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mm, skull -8.2 mm). The injector was left in place for 2 min after each infusion to allow
diffusion from the injector. Time course intervals started immediately upon completion of
kainic acid delivery, and at specified times, animals received an overdose of pentobarbital
(100 mg/kg pentobarbital, intraperitoneally) and were decapitated. The brains were
immersed briefly in ice cold 0.01 M phosphate buffered saline, and the hippocampus was
removed and flash frozen in dry-ice.
Western blot
For the western blots hippocampal tissue was homogenized in a buffer containing a
Complete Protease Inhibitor cocktail (Roche Diagnostics, Indianapolis, IN), and equal
amounts of proteins were electrophoresed on a 4-20% NuPAGE (Invitrogen Life
Technologies) Bis-Tris gel, followed by transfer onto a nitrocellulose membrane (iBlot,
Invitrogen Life Technologies). Membranes were blocked with 5% fat-free milk for 1 h at
room temperature (RT), followed by overnight incubation at 4°C in the following primary
antibodies: TNFR1 (abcam ab19139, 1:1000), TNFR2 (Cell Signaling, Beverly, MA, #3727,
1:1000), CD11b (AbD Serotec, Raleigh, NC, MCA275, 1:1000) or MHC-II (Abcam
ab23990, 1:1000). After washing, the membrane was incubated with anti–mouse IgG (anti-
rabbit IgG for TNFR1/2) conjugated to horseradish peroxidase. The results were visualized
with chemiluminescent substrate (SuperSignal West Femto, Pierce, Rockford, IL). The films
were scanned and densitometry analyzed using the gel analysis function of ImageJ (NIH,
Bethesda, MD). Results were standardized to β-actin (Abcam ab8224, 1:5000) from the
same membrane. Bands were observed at: TNFR1: 52 kDa, TNFR2: 75 kDa, CD11b: 95
kDa, MHC-II: bands of 28-31 kDa, NeuN: 46 and 48 kDa.
Immunohistochemistry and image capture
For TNFR1/TNFR2 immunohistochemistry, brains post-fixed in 4% paraformaldehyde were
paraffin-embedded, and 10 μ thick sections were taken through the dorsal hippocampus. The
sections were baked for 60°C for 2 hours and cooled to RT. Antigen retrieval was performed
in a decloaking chamber (Biocare Medical, Concord, CA) with target retrieval buffer
(DAKO S1699, Carpinteria, CA). After cooling, endogenous peroxidase activity was
quenched by treating the slides with 3% H2O2 for 10 min, then 0.05 M Tris buffer 2×2
minutes. After rinsing, the slides were placed in blocking buffer (DAKO X0909) for 30 min
at RT, followed by incubation overnight in primary antibody at 4°C (TNFR1: Abcam
[Cambridge, MA] ab19139 [1:1000] or TNFR2: Abcam ab15563 (1:50) in antibody diluent
[DAKO S0809]). Subsequently, slides were washed and incubated in a secondary antibody
(biotinylated goat anti-rabbit, Jackson ImmunoResearch, West Grove, PA, 1:500) for 1 hour
at RT and subsequently reacted with avidin-biotin (Vector Labs, Burlingame, CA) followed
by a 3,3′-diaminobenzidine nickel ammonium sulfate solution. Images were captured using
a Nikon Microphot SA with a 2x objective, Nikon DXM 1200 color camera (Nikon,
Melville, NY, USA), and ACT-1 software.
All other immunohistochemistry and image capture was performed as previously described
(Weinberg et al., 2011), for the following antigens: NeuN (Chemicon, Temecula, CA,
1:1000), GFP (Millipore, Bedford, MA, 1:1000), rat IgG (Vector Laboratories, Burlingame,
CA, 1:250), CD11b (AbD Serotec, Raleigh, NC, MCA275, 1:1000), and MHC-II (Abcam
ab23990, 1:1000). Densitometric analysis of IgG extravasation was performed using ImageJ
software (NIH, Bethesda, MD) with a reverse 0-255 scale. Relative densitometry was
calculated based on the densitometry relative to the GFP-treated group average.
Stereological analysis was performed identically as described previously (Weinberg et al.,
2011), using Stereologer software (Stereology Resource Center, Inc., Chester, MD, USA).
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TNFα, and TNFR:Fc subcloning and functional validation
Plasmids containing the coding sequences for rat TNFα (rTNFα, NCBI accession
BC107671) and human TNFα (hTNFα, NCBI accession NM_000594) were purchased from
Open Biosystems (Thermo Scientific, Clone IDs 7938033, LIFESEQ95109283,
respectively). Coding sequences were PCR amplified (Phusion DNA polymerase, New
England Biolabs, Ipswich, MA) using oligomers (Integrated DNA Technologies, Coralville,
Iowa) with AgeI-forward and Not1-reverse overhangs incorporated. Amplicons were
digested with AgeI and NotI restriction enzymes (New England Biolabs) and ligated into
pTR2/CBA-GFP, acquired from the UNC Gene Therapy Center Vector Core. TNFR1:Fc is
a fusion protein composed of the extracellular domain of human type-I TNF receptor fused
to the Fc (fragment crystallizable) region of a mouse IgG1 immunoglobulin molecule.
TNFR1:Fc was PCR amplified from the plasmid pTNFR1:Fc (a kind gift of Dr. Jay K.
Kolls, University of Pittsburgh School of Medicine to the UNC Gene Therapy Center), using
AgeI/NotI primers and ligated into pTR2/CBA identically to the TNFα constructs.
rTNFR2:Fc is a fusion protein composed of the extracellular domain of rat type-2 TNF
receptor fused to the same Fc region as TNFR1:Fc. Rat TNFR2 extracellular domain
(nucleotides 70-843 of NCBI NM_130426.4; OriGene, Rockville, MD) was fused to the
mouse Fc region of TNFR1:Fc using nested PCR reactions. The PCR product then was
ligated into PTR2/CBA. All sequences were verified by the UNC sequencing facility, or
Eton Biosciences (Raleigh, NC).
Functional validation of TNFα and TNFR:Fc constructs
pTR/CBA-GFP, -rTNFα, and -hTNFα and pCMV-rTNFR2 plasmids were PEI-transfected
into 10 cm cultures of Hela cells. Forty eight hours later, conditioned media was spun at
2500xG for 5 min at 4°C to clear cells and debris. Combinations of r/hTNFα and GFP-
conditioned media was incubated with rTNFR2:Fc- or GFP-conditioned media at 4°C for 30
min and subsequently replaced the media of a 24-well plate of Hela cells transfected 24 h
prior with p3X-κB-Luc (firefly luciferase, a kind gift of Dr. Albert Baldwin, UNC Chapel
Hill). Six hours after media transfer, the media was removed and replaced with 100 μL of
Passive Lysis buffer (Promega, Madison, WI). Cells were lysed for 10 min at RT and stored
at -20°C until luciferase assay. For luciferase assay, 100μL of Luciferin (Promega) was
added to 10uL of cell lysis, and read on a Wallac1420 Victor2 automated plate reader.
Results were reported relative to GFP/GFP conditioned media-treated p3X-κB-Luc-
transfected cells.
To test the functionality of TNFR1:Fc, HEK-293 cells conditioned to RPMI 1640 media
(10% FBS, 1% pen/strep) were transfected with pTR2/CBA-rTNFα, pTR/CBA-hTNFα,
pTR/CBA-GFP, or pTR-CBA-TNFR1:Fc plasmids. Media was replaced at 24 h. WEHI-164
clone 13 cells (a cell line highly sensitive to TNFα-induced apoptosis in absence of protein
synthesis, obtained from the University of North Carolina Tissue Culture Facility) were
plated at 2.5E4 cells in 100 μL RPMI 1640 (10% FBS, 1% pen/strep) on a 96-well plate and
incubated 16 h. Media was replaced with 50 μL transfected HEK-293 media (48 h post-
transfection) conditioned from GFP- or TNFR1:Fc-transfected cells, mixed with 8 μg/mL
Actinomycin D (Sigma Aldrich, St. Louis, MO). An additional 50 μL of HEK-293 media
conditioned from GFP, rTNFα, or hTNFα transfection was applied undiluted, or diluted to
10%, 1%, and 0.1% concentration in fresh RPMI 1640 media (10% FBS, 1% pen/strep).
Thus, the final concentrations of conditioned media (GFP, rTNFα, hTNFα) ranged from
50%-0.05%, whereas the concentration of the soluble receptor media TNFR1:Fc (and
control GFP media) was held constant at 50% final concentration. Treatments were
performed in triplicate. Twenty four hours after incubation at 37°C, 5% CO2 in a humidified
incubator, 20 uL of MTS solution (Invitrogen, Grand Island, NY) was applied to each well,
incubated for 1 h, and absorbance determined, indicating relative viable cell number. Cell
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viability was determined relative to GFP/GFP-treated cells, which showed no evidence of
the apoptotic shrinkage readily observed in r/hTNFα-treated cells.
Recombinant virus production and quantification
Recombinant AAV vectors were generated using HEK293 cells as described in Grieger and
Samulski (2012). In brief, suspension HEK293 cells were transfected using a triple
transfection method (Grieger et al., 2006), and 48 hours later, purified virus was obtained by
loading the cell lysate onto a modified discontinuous iodixanol gradient. Purified virus was
dialyzed against 1X phosphate-buffered saline (PBS) and 5% sorbitol for 18 hours, and titers
were calculated by qPCR according to established procedures (Grieger and Samulski, 2006).
Intracranial AAV delivery, cannula and electrode placement
Intracranial AAV infusions were performed in a manner similar to intracranial kainic acid
delivery, with the following differences. In order to determine the effects of chronic TNF-α,
rats received 3 μl (2.4E9 vector genomes) AAV5/CBA-GFP -rTNF, -hTNF, or -TNFR:Fc
unilaterally the right dorsal hippocampus (bregma -4.2 mm, lateral -3.0 mm, skull -3.7 mm).
For the seizure studies, these AAV vectors were infused bilaterally. For amygdala-directed
KA treatment, rats were implanted with a guide cannula (12 mm length, 26-gauge stainless
steel implanted over the amygdala bregma -2.7 mm, lateral -4.5 mm, skull -4.2 mm).
Cannulae were fixed with dental cement to three screws in the skull. After surgery an
obturator was placed into the guide cannula extending 0.5 mm beyond the tip of the guide.
Rats recovered for approximately 1 week prior to KA treatment. For amygdala-directed KA,
a 32-gauge microinjector was placed into the cannula such that the tip terminated in the
amygdala. KA (0.5 mg/ml) was administered in a total volume of 0.5 μLinfused over 2.5
min. Subsequent video recordings were generated using Q-See monitoring (Anaheim, CA);
analysis of seizure activity was based on the seizure motor scale of Racine (1972). For the
electrical kindling studies, a waveform generator (World Precision Instruments) delivered a
single 400 microamp bipolar stimulation ( 60 Hz, 1.7 ms pulse interval, pulse width 0.5 ms,
train duration 2 s) using a constant current stimulus isolation unit. Rats were stimulated once
daily, and the post-stimulus seizure duration was timed.
Statistical Analysis
One-way ANOVAs or student t-tests were used for all collected data, with Pearson's
correlation analysis performed for a subset of western blot results. Fisher's Least Significant
Differences test was used as a common Post-hoc test, when omnibus ANOVA p-values were
< 0.05.
Results
Generalized Limbic Seizures Differentially Alter TNFRs and Evoke Immune Responses in
the Hippocampus
TNFR1-like immunoreactivity and TNFR2-like immunoreactivity were found in neuronal
cell layers of the normal hippocampus, but 24 hours after limbic seizure activity was evoked
by amygdala kainic acid infusion, the hippocampus exhibited an apparent increase in
TNFR1-like immunoreactivity and an apparent decrease in TNFR2-like immunoreactivity
(Figure 1 A, B). These observations were validated by Western blot analysis (Figure 1 C, D)
where hippocampal TNFR1 levels increased significantly as compared to controls, while
TNFR2 levels decreased significantly. Although this generalized limbic seizure activity
caused cell damage in the hippocampus 24h-post treatment (data not shown), early cell
death could not be the sole source for these divergent changes in TNFR subtypes, given the
strong negative correlation between hippocampal TNFR1 and TNFR2 protein levels across
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all time points (Fig. 1D, inset). The amygdala initiated limbic seizure activity also evoked a
substantial immune response in the hippocampus. MHCII and CD11b levels were
significantly increased at 8h post-kainic acid (Figure 1 E, F, G).
Effects of Rat or Human TNFα Expression on TNFRs
Previous studies have shown that mouse TNF-α activated both mouse TNFR1 and TNFR2
while human TNF-α (hTNF-α) only activated mouse TNFR1 (Lewis et al. , 1991).
Previously, Childs et al. (2001) showed that a TNFR1-mouse IgG fusion protein selectively
bound TNF-α and prevented TNFR1 receptor activation. Therefore, we constructed a
plasmid that expressed a TNFR2-mouse IgG fusion protein (TNFR2:Fc) in order to
determine the specificity of rat and human TNF-α on rat TNFRs (Figure 2 A). In the
presence of GFP expression, both rTNF-α and hTNF-α significantly stimulated κB-based
gene expression in HeLa cells (Figure 2 B). However, expression of rat TNFR2:Fc fully
blocked rTNF-α-induced κB-luc activity, but did not prevent hTNF-α-induced κB-luc
activity. These results confirmed that as in the mouse, hTNF-α did not bind rat TNFR2.
Effects of Chronic TNFα Expression on TNFRs and Immune Responses in the
Hippocampus
Recombinant adeno-associated virus serotype 5 (rAAV5) vectors were packaged with the
cassettes that expressed rTNF-α, hTNF-α or GFP. As previously shown (Burger et al. ,
2004, Weinberg et al. , 2011), the AAV5 vector supported neuronal GFP gene expression
throughout the dorsal hippocampus, including hilar, CA1 and CA3 cell bodies. One week
after the TNFα vectors were infused into the dorsal hippocampus, chronic rTNF-α
expression caused a robust upregulation of MHC-II in the dorsal hippocampus, while hTNF-
α expression led to a more modest, but clear MHC-II upregulation (Figure 3 A). Similarly,
chronic rTNF-α or hTNF-α expression increased CD11b immunostaining with rTNF-α
causing a more robust CD11b response than hTNF-α. Also, as previously demonstrated
after acute TNF-α administration (Wright and Merchant, 1994), chronic rTNF-α or hTNF-α
expression in the dorsal hippocampus led to significant IgG extravasation into the
parenchyma distinct from any injection artifact (Figure 3 A, B). In contrast to the results
after limbic seizure activity, one week after hippocampal infusion of either AAV-rTNF-α or
AAV-hTNF-α vectors, western blots showed a significant reduction in TNFR1 but no
change in TNFR2 (Figure 4). Surprisingly, the presence of this elevated immune milieu and
compromised blood-brain barrier did not cause neuronal cell death throughout any of the
dorsal hippocampus after 1 week (Figure 3 A), or as long as 7 weeks after vector delivery
(data not shown).
The Effects of Chronic TNFα Expression on In Vivo Seizure Sensitivity
Although chronic hippocampal expression of rTNF-α or hTNF-α alone did not prove
sufficient to cause cell death or elicit spontaneous limbic seizure activity (data not shown),
subsequent studies identified significant interactions of chronic TNF-α expression on
seizure susceptibility. Initially, rTNF-α or hTNF-α vectors were injected bilaterally into the
dorsal hippocampus, and one week later the rats received a 0.5 μL infusion of kainic acid
(0.5μg/μL) into the amygdala. Chronic rTNF-α expression in the hippocampus did not
produce any difference in the number or duration of kainic acid-induced limbic seizure
activity, but chronic hTNF-α expression caused a significant increase in the number of class
IV seizures (Racine, 1972)(Figure 5 A). When limbic seizures were elicited by electrical
kindling of the amygdala, prior chronic hippocampal expression of rTNF-α significantly
increased the number of electrical stimulations necessary for rats to exhibit three sequential
class IV seizures, while hippocampal hTNFα expression significantly reduced the number
of kindling stimulations needed to elicit three sequential class IV seizures (Figure 5 B).
Despite this reduced number of stimulations necessary to elicit class IV seizures, the average
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seizure duration was significantly longer in hTNF-α treated rats versus control rats or rTNF-
α treated rats (Figure 5 C).
Influence of Endogenous TNF-α on Seizure-induced Cell Death and Seizure Sensitivity
In order to determine the influence of endogenous TNF-α on seizure activity, we utilized a
fusion TNFR1:Fc molecule. Initially, in vitro studies were conducted to verify the biological
activity of AAV vector-derived TNFR1:Fc. We incubated GFP, rTNF-α, and hTNF-α
containing conditioned media with either GFP or TNFR1:Fc containing medium, and
applied the combined media to WEHI-164 clone 13 cells. rTNF-α or hTNF-α conditioned
media led to significant apoptosis in the WEHI-164 as compared to GFP-treated cells, but
incubation of either rTNF-α or hTNF-α with TNFR1:Fc prevented TNF-α-induced
apoptosis (Figure 6 A). Given this in vitro validation of biological activity, we infused
AAV5-TNFR1:Fc vectors 1 week prior to amygdala kainic acid administration. TNFR1:Fc
expression significantly reduced the seizure-induced cell death relative to AAV5-GFP
(Figure 6 B). However, unilateral infusion of AAV5-TNFR1:Fc did not alter the seizure
response to ipsilateral amygdala kainic acid, and bilateral hippocampal AAV5-TNFR1:Fc
infusion did not alter the course of electrical amygdala kindling 1 week post-vector
treatment either in the rate of kindling or seizure duration (Figure 6 C).
Discussion
Over the past decade conclusive evidence indicates that not only do seizures cause long-term
neuroimmune consequences but that some immune factors can produce pro-convulsive
actions (Balosso et al. , 2005, Crespel et al. , 2002, Ravizza et al. , 2008, Yamamoto et al. ,
2006). Given the chronic elevation of TNF-α activity in resected temporal lobe epileptics
(Yamamoto et al., 2006), we investigated the interplay of limbic seizures and hippocampal
TNF-α activity. Overall, the studies show that limbic seizures cause a pro-convulsant
change in TNFRs, and chronic in vivo expression of TNF-α increases in vivo seizure
sensitivity through TNFR1 activation. In contrast, blockade of endogenous TNF-α
significantly attenuates seizure-induced cell death, while activation of TNFR2 exerts an anti-
seizure effect in vivo.
Seizures and TNFR Expression Patterns in the Hippocampus
When limbic seizures were elicited by amygdala kainic acid, subsequent seizure
generalization into the hippocampus caused a significant increase in hippocampal TNFR1
with a concomitant decrease in hippocampal TNFR2. Previous studies by Balosso et al.
(2005) found that transgenic TNFR1 deficient mice were less seizure-responsive to kainic
acid, while mice lacking TNFR2 exhibit a greater kainic acid seizure susceptibility. Thus,
the combination of increased TNFR1 with decreased TNFR2 should create a pro-convulsant
state in the hippocampus. This pro-convulsant state, however, was not a result of chronic
TNF-α expression alone, because chronic rTNF-α or hTNF-α overexpression caused a
decrease in hippocampal TNFR1 and no change in TNFR2. Given this divergence between
seizures and AAV mediated chronic TNF-α exposure, seizure-induced changes in TNFRs
inevitably involve additional, endogenous factors, such as the release of interleukin 1-β
(Vezzani et al. , 2011).
Chronic Activation of Hippocampal TNFRs
Even though AAV vector mediated TNF-α expression likely does not exactly recapitulate
the chronic seizure milieu, observed changes do closely reflect the chronic inflammatory
state seen in resected temporal lobe tissue. In naïve rats AAV mediated hTNF-α or rTNF-α
overexpression caused significant microglial activation and increased blood-brain barrier
(BBB) permeability. Surprisingly, this state of chronic inflammation and BBB compromise
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did not result in any overt cell death. Generally, TNFR1 activation initiates the recruitment
of TNF receptor-associated death domain (TRADD), a Fas-associated death domain protein
(FADD) and subsequent caspase 8 induced apoptosis. However, the TRADD also can
recruit receptor-interacting protein 1, which through interactions with TNFR associated
factor 2 causes NF-κB activation, cellular proliferation and inflammation (Naude et al.,
2011) . Obviously, chronic expression of hTNF-α in neurons was not sufficient to activate
TNFR1 mediated apoptosis. Similarly, substantial evidence has established that
experimentally induced BBB breakdown can directly induce epileptic foci (Seiffert et al.,
2004), but the significant compromise in BBB function induced by chronic TNF-α
overexpression did not result in spontaneous seizure activity. Therefore, in the absence of
additional insults BBB compromise alone did not prove sufficient to elicit seizure activity.
However, this BBB compromise likely contributed to the in vivo seizure sensitivity, as
previously demonstrated (Marchi et al. , 2007, van Vliet et al. , 2007). Finally, the vector
mediated expression is almost entirely neuronal in nature, so these overall findings clearly
contrast the phenotype of transgenic mice where neuronal overexpression of TNF-α resulted
in seizures and early mortality (Probert et al. , 1995).
Chronic TNFR Activation Influences Seizure Sensitivity
In two different limbic seizure models chronic expression of hTNF-α, a TNFR1-specific
ligand, significantly increased seizure sensitivity. Significant increases were found both in
the number of seizures after amygdala kainic acid administration and in the kindling rate and
seizure duration in the electrical amygdala kindling model. Obviously, chronic, selective
activation of TNFR1 increased in vivo seizure sensitivity, in contrast to acute TNFR1
activation which did not influence kainic acid-induced seizures (Balosso et al. , 2005).
Certainly, resected tissue from patients with temporal lobe epilepsy have increased TNFR1
protein expression and increased TNFR1-signaling (Yamamoto et al. , 2006). Thus, the
presence of elevated TNF-α would favor activation of TNFR1 leading to an increase in
seizure sensitivity. In contrast, chronic activation of both TNFR1 and TNFR2 by rTNF-α
overexpression significantly decreased the rate of amygdala kindling. As suggested
previously (Balosso et al., 2005) activation of TNFR2 appears to exert an anti-seizure action
in vivo, even with concomitant TNFR1 activation by chronic rTNF-α expression.
Effects of Blocking Seizure-induced TNFα Activity in the Hippocampus
By chronically expressing a potent decoy receptor for TNF-α, we were able to evaluate the
role of endogenous TNF-α release on seizure-induced cell death and in vivo seizure
sensitivity. Hippocampal-specific expression of the decoy TNF-α significantly suppressed
seizure-induced cell death in both the hilus and CA3. This finding not only supports
previous studies where TNF-α proved important for modulation of cell death in these
neuronal populations (Shinoda et al. , 2003), but also validates the in vivo activity of the
vector derived decoy TNF receptor. Previous studies have found that TNFR1 or TNFR1/R2
knockout mice actually exhibit an increased cell death in response to excitotoxic insult
(Bruce et al. , 1996, Gary et al. , 1998). These contrasting results likely arise from
differences between partial blockade of TNF-α function using soluble receptor-antibody
chimeras versus unconditional loss of receptor activity over the course of development.
TNF-α blockade, however, did not alter seizure activity in either the kainic acid or
amygdala kindling models. Both kainic acid-induced seizures and amygdala-kindled
seizures increase the expression of TNF-α (Minami et al. , 1991; Plata-Salaman et al. ,
2000), which would be expected to activate both TNFR1 and TNFR2. Although attenuation
of TNF-α actions on TNFR1 would reduce the pro-seizure influence of TNFR1,
simultaneous reduction of TNF-α actions on TNFR2 would reduce the anti-seizure actions
mediated through the TNFR2 receptor. Alternatively, the localized attenuation of TNF-α
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may not prove sufficient to alter the broad systems-level plasticity required for generalized
limbic seizures. For example, Riazi (2008) reported a significant anti-seizure effect of effect
of TNF-α neutralizing antibodies when the antibodies were administered intraventricularly.
Conclusions
Our findings show that after limbic seizures, hippocampal TNFR1 protein expression
increases and TNFR2 protein expression decreases, a change that should favor a pro-
convulsant state. In addition, chronic hippocampal TNFR1 activation induces an increased
seizure propensity in two limbic seizure models. Chronic activation of TNFR1/2, however,
exerts anti-seizure properties, even in the context of presumptive, simultaneous activation of
TNFR1. With regard to endogenous TNF-α, vector mediated expression of a decoy TNFR1
prevented seizure-induced cell death, but did not alter in vivo seizure sensitivity. Thus,
blockade of endogenous TNF-α should attenuate seizure-induced pathology, whereas
attenuation of seizure activity will likely require selective activation of TNFR2.
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• Limbic seizures increase type 1 TNF receptors, but decrease type 2 TNF
receptors.
• TNF overexpression increases microglial activation and BBB compromise.
• Chronic activation of type 1 TNF receptors increases seizure sensitivity.
• Chronic activation of type 2 TNF receptors decreases seizure sensitivity.
• Blockade of endogenous TNF significantly reduces seizure-induced cell death.
Weinberg et al. Page 12













Figure 1. Seizures alter TNFR1 and TNFR2 protein expression and immune activation in the
hippocampus
Panels A and B show immunostaining of TNFR1 and TNFR2, respectively, in the dorsal
hippocampus in control and kainic-acid treated rats 24 h post-treatment. Panel C shows
western blots probing TNFR1 and TNFR2 expression in whole hippocampus homogenates
in rats at 0, 3, 8, or 24 h post-kainic acid. β-actin expression was used to determine protein
loading. Panel D shows average relative TNF-α receptor expression, based on densitometric
analysis. The inset indicates a strong inverse correlation of TNFR1 protein expression to
TNFR2 expression across all animals. Panel E shows western blots probing MHC-II and
CD11-b expression in whole hippocampus homogenates in rats at 0, 3, 8, or 24 h post-kainic
acid. Panels F and G show average relative MHC-II and CD11-b expression, respectively,
based on densitometric analysis. ***, *, Significantly different from untreated control group
(P < 0.01, < 0.05, respectively). Error bars represent the standard error of the mean.
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Figure 2. Rat TNFR2 is targeted by rat, but not human TNFα
Panel A, top: diagram of the chimeric rat TNFR2 extracellular domain linked to an IgG Fc
domain. A linker peptide allows for flexibility of the receptor extracellular domain. Panel A,
bottom left: Rat TNFR2:Fc binds to rat TNFα (rTNFα), preventing luciferase expression in
κB-luciferase transfected HeLa cells. Panel A, bottom right: Rat TNFR2:Fc does not bind to
human TNFα (hTNFα), which activates luciferase expression in κB-luciferase transfected
HeLa cells. Panel B shows relative light units read in HeLa cell lysates. GFP/GFP refers to
the condition in which conditioned media from GFP transfected cells (control for rTNFα or
hTNFα) was incubated with conditioned media from GFP transfected cells (control for
TNFR2:Fc). ***, Significantly different from GFP/GFP group (P < 0.01). Error bars
represent the standard error of the mean.
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Figure 3. Effect of chronic TNFα expression on hippocampal inflammation, IgG extravasation
and neuronal viability
Representative images show the dorsal hippocampi from AAV5-GFP, rTNFα, or hTNFα-
treated rats immunostained for MHC-II, CD11-b, IgG, or NeuN. There was very high MHC-
II expression in rTNFα-treated rats, throughout, but limited to, the hippocampus. There was
much less relative MHC-II expression in the hippocampus of hTNFα-treated rats, but MHC-
II-positive cells still were present throughout the AAV-transduced area. No MHC-II-positive
cells were found in GFP-treated rats. CD11b showed a similar pattern as MHC-II, but
immunoreactivity was less robust. IgG extravasation was markedly elevated in both TNFα-
treated groups as compared to the GFP-treated control. An arrow indicates the needle tract
seen in the GFP-treated animal which illustrates the relative lack of any injection effect
alone on IgG extravasation. However, there was no evidence of cell death (NeuN). Panel B
shows that IgG was significantly elevated in both the rTNF-α and hTNF-α overexpressing
groups versus the GFP controls. ***, *, Significantly different from untreated control group
(P < 0.01, < 0.05, respectively). Error bars represent the standard error of the mean.
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Figure 4. Effects of rat or human TNF-α expression on hippocampal TNFR1 and TNFR2
Panel A shows western blots probing TNFR1 and TNFR2 expression in whole hippocampus
homogenates in rats 1 week post-AAV delivery. The AAV-based transgenes are listed as
column heads. Panel B shows the densitometric analysis of western blot results, which
clearly show a relative decrease of TNFR1 protein after chronic rTNFα or hTNFα
expression, but no change in TNFR2 expression. ***, *, Significantly different (P < 0.01, <
0.05, respectively). Error bars represent the standard error of the mean.
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Figure 5. Effect of chronic TNFα expression on limbic seizures
Panel A shows that after amygdala delivery of kainic acid to AAV5-GFP, rTNF-α, or
hTNF-α treated rats, hTNF-α treated rats exhibited significantly more class IV seizures than
either GFP or rTNF-α treated rats. Panel B shows that compared to GFP treated rats a
greater number of stimulations was necessary to elicit three class IV seizures in rTNF-α
treated rats, whereas fewer stimulations were necessary to elicit three class IV seizures in
hTNFα-treated rats. Panel C shows that the average duration of class IV seizures in kindled
rats was longer in hTNFα-treated rats. ***, *, Significantly different from GFP group. Error
bars represent the standard error of the mean.
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Figure 6. In vitro validation and in vivo effect of soluble decoy TNFR1:Fc expression on seizure-
induced neuronal cell death and limbic seizures
Panel A shows that in vitro, TNFR1:Fc blocks the function of rat and human TNFα,
preventing apoptosis in WEHI 164 clone 13 cells. ***, Significantly different from GFP/
GFP group (P < 0.01). Panel B shows that kainic acid-induced cell death is reduced in the
hilus and CA3 in rats previously administered AAV5-TNFR1:Fc in the dorsal hippocampus
as compared to AAV5-GFP- treated rats. Panel C shows that kainic acid-induced seizures,
amygdala kindling, and average kindled seizure duration were similar in AAV5-TNFR1:Fc-
treated and –GFP-treated rats. ***, *, Significantly different from GFP control (P < 0.01, <
0.05, respectively). Error bars represent the standard error of the mean.
Weinberg et al. Page 18
Exp Neurol. Author manuscript; available in PMC 2014 September 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
